Unknown.png
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
02 oct. 2024 08h00 HE | CervoMed Inc.
BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that Dr. John...
Unknown.png
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
26 sept. 2024 08h00 HE | CervoMed Inc.
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will...
Unknown.png
CervoMed to Participate in Upcoming Investor Conferences
27 août 2024 08h30 HE | CervoMed Inc.
BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the...
Unknown.png
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
22 août 2024 08h00 HE | CervoMed Inc.
BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent...
Unknown.png
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
12 août 2024 08h00 HE | CervoMed Inc.
- Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in June 2024; topline data expected in December...
Unknown.png
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
30 juil. 2024 08h00 HE | CervoMed Inc.
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s...
Unknown.png
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
29 juil. 2024 08h00 HE | CervoMed Inc.
- Baseline data from the AscenD-LB Phase 2a trial in DLB demonstrated that plasma glial fibrillary acidic protein (GFAP) was highly correlated to scores on the CDR-SB; plasma GFAP shown to increase...
Unknown.png
CervoMed to Participate in the Emerging Growth Conference
17 juil. 2024 08h00 HE | CervoMed Inc.
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s...
Unknown.png
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
11 juil. 2024 08h51 HE | CervoMed Inc.
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data expected in December 2024 BOSTON, July 11, 2024 (GLOBE NEWSWIRE) --...
Unknown.png
CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes
24 juin 2024 08h00 HE | CervoMed Inc.
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its expected...